Eintrag weiter verarbeiten
Structural Basis for the Exceptional in vivo Efficacy of Bisphosphonate Drugs
Gespeichert in:
| Zeitschriftentitel: | ChemMedChem |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , |
| In: | ChemMedChem, 1, 2006, 2, S. 267-273 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Rondeau, Jean‐Michel Bitsch, Francis Bourgier, Emmanuelle Geiser, Martin Hemmig, Rene Kroemer, Markus Lehmann, Sylvie Ramage, Paul Rieffel, Sebastien Strauss, André Green, Jonathan R. Jahnke, Wolfgang Rondeau, Jean‐Michel Bitsch, Francis Bourgier, Emmanuelle Geiser, Martin Hemmig, Rene Kroemer, Markus Lehmann, Sylvie Ramage, Paul Rieffel, Sebastien Strauss, André Green, Jonathan R. Jahnke, Wolfgang |
|---|---|
| author |
Rondeau, Jean‐Michel Bitsch, Francis Bourgier, Emmanuelle Geiser, Martin Hemmig, Rene Kroemer, Markus Lehmann, Sylvie Ramage, Paul Rieffel, Sebastien Strauss, André Green, Jonathan R. Jahnke, Wolfgang |
| spellingShingle |
Rondeau, Jean‐Michel Bitsch, Francis Bourgier, Emmanuelle Geiser, Martin Hemmig, Rene Kroemer, Markus Lehmann, Sylvie Ramage, Paul Rieffel, Sebastien Strauss, André Green, Jonathan R. Jahnke, Wolfgang ChemMedChem Structural Basis for the Exceptional in vivo Efficacy of Bisphosphonate Drugs Organic Chemistry General Pharmacology, Toxicology and Pharmaceutics Molecular Medicine Drug Discovery Biochemistry Pharmacology |
| author_sort |
rondeau, jean‐michel |
| spelling |
Rondeau, Jean‐Michel Bitsch, Francis Bourgier, Emmanuelle Geiser, Martin Hemmig, Rene Kroemer, Markus Lehmann, Sylvie Ramage, Paul Rieffel, Sebastien Strauss, André Green, Jonathan R. Jahnke, Wolfgang 1860-7179 1860-7187 Wiley Organic Chemistry General Pharmacology, Toxicology and Pharmaceutics Molecular Medicine Drug Discovery Biochemistry Pharmacology http://dx.doi.org/10.1002/cmdc.200500059 <jats:title>Abstract</jats:title><jats:p><jats:italic>To understand the structural basis for bisphosphonate therapy of bone diseases, we solved the crystal structures of human farnesyl pyrophosphate synthase (FPPS) in its unliganded state, in complex with the nitrogen‐containing bisphosphonate (N‐BP) drugs zoledronate, pamidronate, alendronate, and ibandronate, and in the ternary complex with zoledronate and the substrate isopentenyl pyrophosphate (IPP). By revealing three structural snapshots of the enzyme catalytic cycle, each associated with a distinct conformational state, and details about the interactions with N‐BPs, these structures provide a novel understanding of the mechanism of FPPS catalysis and inhibition. In particular, the accumulating substrate, IPP, was found to bind to and stabilize the FPPS–N‐BP complexes rather than to compete with and displace the N‐BP inhibitor. Stabilization of the FPPS–N‐BP complex through IPP binding is supported by differential scanning calorimetry analyses of a set of representative N‐BPs. Among other factors such as high binding affinity for bone mineral, this particular mode of FPPS inhibition contributes to the exceptional in vivo efficacy of N‐BP drugs. Moreover, our data form the basis for structure‐guided design of optimized N‐BPs with improved pharmacological properties.</jats:italic></jats:p> Structural Basis for the Exceptional in vivo Efficacy of Bisphosphonate Drugs ChemMedChem |
| doi_str_mv |
10.1002/cmdc.200500059 |
| facet_avail |
Online |
| finc_class_facet |
Chemie und Pharmazie Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9jbWRjLjIwMDUwMDA1OQ |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9jbWRjLjIwMDUwMDA1OQ |
| institution |
DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 |
| imprint |
Wiley, 2006 |
| imprint_str_mv |
Wiley, 2006 |
| issn |
1860-7179 1860-7187 |
| issn_str_mv |
1860-7179 1860-7187 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
rondeau2006structuralbasisfortheexceptionalinvivoefficacyofbisphosphonatedrugs |
| publishDateSort |
2006 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
ChemMedChem |
| source_id |
49 |
| title |
Structural Basis for the Exceptional in vivo Efficacy of Bisphosphonate Drugs |
| title_unstemmed |
Structural Basis for the Exceptional in vivo Efficacy of Bisphosphonate Drugs |
| title_full |
Structural Basis for the Exceptional in vivo Efficacy of Bisphosphonate Drugs |
| title_fullStr |
Structural Basis for the Exceptional in vivo Efficacy of Bisphosphonate Drugs |
| title_full_unstemmed |
Structural Basis for the Exceptional in vivo Efficacy of Bisphosphonate Drugs |
| title_short |
Structural Basis for the Exceptional in vivo Efficacy of Bisphosphonate Drugs |
| title_sort |
structural basis for the exceptional in vivo efficacy of bisphosphonate drugs |
| topic |
Organic Chemistry General Pharmacology, Toxicology and Pharmaceutics Molecular Medicine Drug Discovery Biochemistry Pharmacology |
| url |
http://dx.doi.org/10.1002/cmdc.200500059 |
| publishDate |
2006 |
| physical |
267-273 |
| description |
<jats:title>Abstract</jats:title><jats:p><jats:italic>To understand the structural basis for bisphosphonate therapy of bone diseases, we solved the crystal structures of human farnesyl pyrophosphate synthase (FPPS) in its unliganded state, in complex with the nitrogen‐containing bisphosphonate (N‐BP) drugs zoledronate, pamidronate, alendronate, and ibandronate, and in the ternary complex with zoledronate and the substrate isopentenyl pyrophosphate (IPP). By revealing three structural snapshots of the enzyme catalytic cycle, each associated with a distinct conformational state, and details about the interactions with N‐BPs, these structures provide a novel understanding of the mechanism of FPPS catalysis and inhibition. In particular, the accumulating substrate, IPP, was found to bind to and stabilize the FPPS–N‐BP complexes rather than to compete with and displace the N‐BP inhibitor. Stabilization of the FPPS–N‐BP complex through IPP binding is supported by differential scanning calorimetry analyses of a set of representative N‐BPs. Among other factors such as high binding affinity for bone mineral, this particular mode of FPPS inhibition contributes to the exceptional in vivo efficacy of N‐BP drugs. Moreover, our data form the basis for structure‐guided design of optimized N‐BPs with improved pharmacological properties.</jats:italic></jats:p> |
| container_issue |
2 |
| container_start_page |
267 |
| container_title |
ChemMedChem |
| container_volume |
1 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792348036188340227 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T18:04:01.537Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Structural+Basis+for+the+Exceptional+in%E2%80%85vivo+Efficacy+of+Bisphosphonate+Drugs&rft.date=2006-02-13&genre=article&issn=1860-7187&volume=1&issue=2&spage=267&epage=273&pages=267-273&jtitle=ChemMedChem&atitle=Structural+Basis+for+the+Exceptional+in%E2%80%85vivo+Efficacy+of+Bisphosphonate+Drugs&aulast=Jahnke&aufirst=Wolfgang&rft_id=info%3Adoi%2F10.1002%2Fcmdc.200500059&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792348036188340227 |
| author | Rondeau, Jean‐Michel, Bitsch, Francis, Bourgier, Emmanuelle, Geiser, Martin, Hemmig, Rene, Kroemer, Markus, Lehmann, Sylvie, Ramage, Paul, Rieffel, Sebastien, Strauss, André, Green, Jonathan R., Jahnke, Wolfgang |
| author_facet | Rondeau, Jean‐Michel, Bitsch, Francis, Bourgier, Emmanuelle, Geiser, Martin, Hemmig, Rene, Kroemer, Markus, Lehmann, Sylvie, Ramage, Paul, Rieffel, Sebastien, Strauss, André, Green, Jonathan R., Jahnke, Wolfgang, Rondeau, Jean‐Michel, Bitsch, Francis, Bourgier, Emmanuelle, Geiser, Martin, Hemmig, Rene, Kroemer, Markus, Lehmann, Sylvie, Ramage, Paul, Rieffel, Sebastien, Strauss, André, Green, Jonathan R., Jahnke, Wolfgang |
| author_sort | rondeau, jean‐michel |
| container_issue | 2 |
| container_start_page | 267 |
| container_title | ChemMedChem |
| container_volume | 1 |
| description | <jats:title>Abstract</jats:title><jats:p><jats:italic>To understand the structural basis for bisphosphonate therapy of bone diseases, we solved the crystal structures of human farnesyl pyrophosphate synthase (FPPS) in its unliganded state, in complex with the nitrogen‐containing bisphosphonate (N‐BP) drugs zoledronate, pamidronate, alendronate, and ibandronate, and in the ternary complex with zoledronate and the substrate isopentenyl pyrophosphate (IPP). By revealing three structural snapshots of the enzyme catalytic cycle, each associated with a distinct conformational state, and details about the interactions with N‐BPs, these structures provide a novel understanding of the mechanism of FPPS catalysis and inhibition. In particular, the accumulating substrate, IPP, was found to bind to and stabilize the FPPS–N‐BP complexes rather than to compete with and displace the N‐BP inhibitor. Stabilization of the FPPS–N‐BP complex through IPP binding is supported by differential scanning calorimetry analyses of a set of representative N‐BPs. Among other factors such as high binding affinity for bone mineral, this particular mode of FPPS inhibition contributes to the exceptional in vivo efficacy of N‐BP drugs. Moreover, our data form the basis for structure‐guided design of optimized N‐BPs with improved pharmacological properties.</jats:italic></jats:p> |
| doi_str_mv | 10.1002/cmdc.200500059 |
| facet_avail | Online |
| finc_class_facet | Chemie und Pharmazie, Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9jbWRjLjIwMDUwMDA1OQ |
| imprint | Wiley, 2006 |
| imprint_str_mv | Wiley, 2006 |
| institution | DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1 |
| issn | 1860-7179, 1860-7187 |
| issn_str_mv | 1860-7179, 1860-7187 |
| language | English |
| last_indexed | 2024-03-01T18:04:01.537Z |
| match_str | rondeau2006structuralbasisfortheexceptionalinvivoefficacyofbisphosphonatedrugs |
| mega_collection | Wiley (CrossRef) |
| physical | 267-273 |
| publishDate | 2006 |
| publishDateSort | 2006 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | ChemMedChem |
| source_id | 49 |
| spelling | Rondeau, Jean‐Michel Bitsch, Francis Bourgier, Emmanuelle Geiser, Martin Hemmig, Rene Kroemer, Markus Lehmann, Sylvie Ramage, Paul Rieffel, Sebastien Strauss, André Green, Jonathan R. Jahnke, Wolfgang 1860-7179 1860-7187 Wiley Organic Chemistry General Pharmacology, Toxicology and Pharmaceutics Molecular Medicine Drug Discovery Biochemistry Pharmacology http://dx.doi.org/10.1002/cmdc.200500059 <jats:title>Abstract</jats:title><jats:p><jats:italic>To understand the structural basis for bisphosphonate therapy of bone diseases, we solved the crystal structures of human farnesyl pyrophosphate synthase (FPPS) in its unliganded state, in complex with the nitrogen‐containing bisphosphonate (N‐BP) drugs zoledronate, pamidronate, alendronate, and ibandronate, and in the ternary complex with zoledronate and the substrate isopentenyl pyrophosphate (IPP). By revealing three structural snapshots of the enzyme catalytic cycle, each associated with a distinct conformational state, and details about the interactions with N‐BPs, these structures provide a novel understanding of the mechanism of FPPS catalysis and inhibition. In particular, the accumulating substrate, IPP, was found to bind to and stabilize the FPPS–N‐BP complexes rather than to compete with and displace the N‐BP inhibitor. Stabilization of the FPPS–N‐BP complex through IPP binding is supported by differential scanning calorimetry analyses of a set of representative N‐BPs. Among other factors such as high binding affinity for bone mineral, this particular mode of FPPS inhibition contributes to the exceptional in vivo efficacy of N‐BP drugs. Moreover, our data form the basis for structure‐guided design of optimized N‐BPs with improved pharmacological properties.</jats:italic></jats:p> Structural Basis for the Exceptional in vivo Efficacy of Bisphosphonate Drugs ChemMedChem |
| spellingShingle | Rondeau, Jean‐Michel, Bitsch, Francis, Bourgier, Emmanuelle, Geiser, Martin, Hemmig, Rene, Kroemer, Markus, Lehmann, Sylvie, Ramage, Paul, Rieffel, Sebastien, Strauss, André, Green, Jonathan R., Jahnke, Wolfgang, ChemMedChem, Structural Basis for the Exceptional in vivo Efficacy of Bisphosphonate Drugs, Organic Chemistry, General Pharmacology, Toxicology and Pharmaceutics, Molecular Medicine, Drug Discovery, Biochemistry, Pharmacology |
| title | Structural Basis for the Exceptional in vivo Efficacy of Bisphosphonate Drugs |
| title_full | Structural Basis for the Exceptional in vivo Efficacy of Bisphosphonate Drugs |
| title_fullStr | Structural Basis for the Exceptional in vivo Efficacy of Bisphosphonate Drugs |
| title_full_unstemmed | Structural Basis for the Exceptional in vivo Efficacy of Bisphosphonate Drugs |
| title_short | Structural Basis for the Exceptional in vivo Efficacy of Bisphosphonate Drugs |
| title_sort | structural basis for the exceptional in vivo efficacy of bisphosphonate drugs |
| title_unstemmed | Structural Basis for the Exceptional in vivo Efficacy of Bisphosphonate Drugs |
| topic | Organic Chemistry, General Pharmacology, Toxicology and Pharmaceutics, Molecular Medicine, Drug Discovery, Biochemistry, Pharmacology |
| url | http://dx.doi.org/10.1002/cmdc.200500059 |